Drug maker Pfizer launches migraine medication in India

Drug maker Pfizer said on Monday that it has launched a new migraine medication in India. Introducing Rimegepant ODT for adults who have not responded adequately to triptans, the standard class of drugs used for migraine treatment, the company said the new therapy was designed to offer rapid and long-lasting relief without the risks associated with the “overuse” of traditional medicines.

Rimegepant is set to be available as a 75-mg orally disintegrating tablet (ODT), making it suitable for people who need quick relief, while on the move. According to Pfizer, the medication provides pain relief that can last up to 48 hours after treatment, and helps patients return to normal sooner by easing key symptoms associated with migraine.

Pfizer Ltd (India) managing director Meenakshi Nevatia said the new treatment had the potential to significantly improve patients’ quality of life. “We are excited to bring Rimegepant to India. Its potential impact on people living with migraine will be tremendous. We believe this treatment will help people with migraine manage pain more effectively and reclaim productive days sooner than with currently available options,” she said.